Sign in
WithdrawnPhase 1/2

A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

Key facts

Who runs it
Peking Union Medical College Hospital
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
Aug 2023
Expected to end
Dec 2026
Type of study
Interventional
Treatments tested
  • Roxadustat in combination with retinoic acid
Record updated
7 July 2026
Why it stopped
The study has not actually been conducted.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Low-risk MDS unresponsive to first-line therapy

Who cannot take part

  • Severe heart and kidney function bu'quan
  • myelofibrosis

About the trial

What the trial wants to find out

Roxadustat has been approved for low-risk MDS clinical trials, but the trial results are not available. For refractory low-risk MDS, the effective rate of roxadustat treatment is about 20-30%, and roxadustat combined with retinoic acid may have better efficacy in the treatment of refractory low-risk MDS.

The group in the trial

  • Roxadustat combined with retinoic acid groupTreatment being tested

    Treatment: Roxadustat in combination with retinoic acid

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
7 July 2026